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Abstract
Background: Inflammation has been implicated in cardiovascular disease, and the important role of proteasomes
in the development of inflammation and other macrophage functions has been demonstrated. Tocotrienols are
potent hypocholesterolemic agents that inhibit b-hydroxy-b-methylglutaryl coenzyme A reductase activity, which is
degraded via the ubiquitin-proteasome pathway. Our objective was to evaluate the effect of tocotrienols in
reducing inflammation. Lipopolysaccharide (LPS) was used as a prototype for inflammation in murine RAW 264.7
cells and BALB/c female mice.
Results: The present results clearly demonstrate that a-, g-, or δ-tocotrienol treatments inhibit the chymotrypsin-
like activity of 20 S rabbit muscle proteasomes (> 50%; P < 0.05). Chymotrypsin, trypsin, and post-glutamase
activities were decreased > 40% (P < 0.05) with low concentrations (< 80 μM), and then increased gradually with
concentrations of (80 - 640 μM) in RAW 264.7 whole cells. Tocotrienols showed 9 - 33% (P < 0.05) inhibitions in
TNF-a secretion in LPS-stimulated RAW 264.7 cells. Results of experiments carried out in BALB/c mice
demonstrated that serum levels of TNF-a after LPS treatment were also reduced (20 - 48%; P < 0.05) by
tocotrienols with doses of 1 and 10 μg/kg, and a corresponding rise in serum levels of corticosterone (19 - 41%;
P < 0.05) and adrenocorticotropic hormone (81 - 145%; P < 0.02) was observed at higher concentrations (40 μM).
Maximal inhibition of LPS-induced TNF-a was obtained with δ-tocotrienol (10 μg/kg). Low concentrations of
δ-Tocotrienols (< 20 μM) blocked LPS-induced gene expression of TNF-a, IL-1b, IL-6 and iNOS (>40%), while higher
concentrations (40 μM) increased gene expression of the latter in peritoneal macrophages (prepared from BALB/c
mice) as compared to control group.
Conclusions: These results represent a novel approach by using natural products, such as tocotrienols as
proteasome modulators, which may lead to the development of new dietary supplements of tocotrienols for
cardiovascular diseases, as well as others that are based on inflammation.
Background
Lipopolysaccharide (LPS), which is expressed on the
outer membrane of essentially all Gram-negative bac-
teria, is a potent inducer of pro-inflammatory cytokines,
including tumor necrosis factor-a (TNF-a interleukin-
1b (IL-1b), IL-6, IL-8, arachidonic acid metabolites and
nitric oxide [1]. LPS can also induce corticosteroid pro-
duction by the host, which tends to suppress further
production of pro-inflammatory cytokines. Some
conditions leading to dysregulated production of inflam-
matory cytokines by the host can produce profound
alterations in metabolic, cardiovascular, immunological,
haemostatic, and endocrine functions, which may ulti-
mately lead to septic shock [1-3]. Less profound inflam-
matory responses have also been implicated in the
pathogenesis of atherosclerosis, cancer, stroke and dia-
betes in human subjects [4-7].
Proteasomes are essential for numerous physiological
processes, including signal transduction, transcriptional
activation, cell cycle progression, and certain immune
cell functions [8]. We have reported a potentially impor-
tant central role for proteasomes in inflammation and
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as 26 S multi-subunit complexes containing a 20 S pro-
teolytic proteasome and a 19 S regulatory complex. Cor-
respondingly, the 20 S proteasome is comprised of a
variety of distinct protein subunits that account for the
different proteolytic activities of the 20 S proteasome.
Several different exogenous inhibitors or activators of
proteasome function have been described, and these
inhibitors act by blocking, or activating, the proteolytic
activity of the individual protein subunits of the 20 S
proteasome.
We, and others, have reported that tocotrienols inter-
fere with the formation of atherosclerotic plaque, and
possess hypocholesterolemic, antioxidant, anti-inflamma-
tory, antithrombotic, and anti-proliferative (anticancer)
properties [9-22]. Tocotrienols are naturally occurring
compounds containing a chroman ring and a farnesylated
unsaturated side-chain with analogs of a-, b-, g-a n d
δ-type. These tocotrienols are minor constituents of
natural vitamin E (predominantly a-tocopherol) which
has a saturated side-chain attached to a chroman ring
(Figure 1). Tocotrienols lower serum total- and LDL-
cholesterol levels by inhibiting hepatic b-hydroxy-
b-methylglutaryl coenzyme A (HMG-CoA) reductase
activity through a post-transcriptional mechanism, which
induces degradation of the reductase enzyme [19]. An
unsaturated side-chain is essential for inhibition of hepa-
tic HMG-CoA reductase activity. On the other hand,
tocopherols (vitamin E) are well known for their charac-
teristic antioxidant activity, but they do not increase
reductase degradation or lower serum total or LDL-
cholesterol levels [10,16]. The positive effects of tocotrie-
nols as hypocholesterolemic, antioxidant, and anticancer
agents have been confirmed in animal systems and var-
ious cell lines by many investigators [15-22].
Moreover, the far superior efficacy of tocotrienols ver-
sus tocopherols (vitamin E) as antioxidants has been
established, and δ-tocotrienol is found to be the most
potent among the known tocotrienols [10,17,18,22].
Tocotrienols also show non-antioxidant properties in
various in vitro and in vivo models. Perhaps most
importantly, tocotrienols interact with the mevalonate
pathway leading to the lowering of cholesterol levels,
the prevention of cell adhesion to endothelial cells, the
suppression of tumor cell growth, and glutamate-
induced neurotoxicity [10-12,23,24].
The present investigation was carried out to evaluate
the mechanisms by which tocotrienols inhibit inflamma-
tion. Murine systems were chosen in the present study,
because they are relatively resistant to the lethal effects
of endotoxin compared to rabbit and sheep [1,3,25].
Recently, rodent models have been developed which are
very sensitive to bacterial endotoxin and thus, female
mice were chosen due to their increased sensitivity to
LPS-induced inflammation. These experiments were
designed to test our hypothesis that tocotrienol treat-
ment modulates proteasomal activity, induces corticos-
teroids synthesis, and blocks LPS-induced signaling
pathways that contribute to the inflammatory process.
Materials and methods
Reagents
Highly purified, deep rough chemotype LPS (Re LPS)
from E. coli D31m4 was prepared as described by Qur-
eshi et al. [26]. For tissue culture studies, Dulbecco’s
Modified Eagle Medium (DMEM), heat-inactivated
low-endotoxin fetal bovine serum (FBS), and gentami-
cin were all purchased from Cambrex (Walkersville,
MD). Thioglycollate was purchased from Sigma,
Aldrich (St. Louis, MO) and the RNeasy mini kit from
QIAGEN sciences (Germantown, MD). Substrates for
the chymotrypsin-like activity of the proteasome were
p u r c h a s e df r o mC a l b i o c h e m( L aJ o l l a ,C A ) .T o c o t r i e n o l
rich fractions (TRF) of palm oil were provided by
Malaysian Palm Oil Board, Kuala Lumpur, Malaysia
(previously known as “Palm Oil Research Institute of
Malaysia” [PORIM], Kuala Lumpur, Malaysia). “Protea-
some-Glo” assays kits for chymotrypsin-like activity
(substrate: Suc LLVY-Glo, Succinyl-leucine-leucine-
valine-tyrosine-aminoluciferin), trypsin-like activity
(Z-LRR aminoluciferin, Z-leucine-arginine-arginine-
aminoluciferin), and post-glutamase activity (post-acidic,
substrate, ZnLPnLD-Glo, Z-norleucine-proline-norleu-
cine-aspartate-aminoluciferin) of the proteasome were
purchased from Promega (Madison, WI). RAW 264.7 cells
(TIB 71) were purchased from American Type Culture
Collection (Manassas, VA), and 4-week-old BALB/c
female mice were obtained from The Jackson Laboratory
(Bar Harbor, ME).
Figure 1 Chemical structures of various isomers of tocopherols
and tocotrienols.
Qureshi et al. Lipids in Health and Disease 2010, 9:143
http://www.lipidworld.com/content/9/1/143
Page 2 of 15Purification of a-tocopherol, a-, g-, and δ-tocotrienols
from TRF of palm oil
The individual components of tocotrienol rich fraction
(TRF) of palm oil were purified as described recently
[10]. The purity of a-tocopherol and individual toco-
trienols were established by high pressure liquid chro-
matography (HPLC) against their respective pure
standards [10].
Effects of various tocols (tocopherols + tocotrienols) on
the chymotrypsin-like activity of 20 S rabbit muscle
proteasomes
Proteasomal activities of the 20 S rabbit muscle protea-
somes (0.4 μg/mL) were assayed with synthetic peptide
substrates in 0.02 M Tris-HCl buffer (pH 7.2). The sub-
strate used for the chymotrypsin-like activity was 100 μM
of succinyl-Leu-Leu-Val-Tyr-amino-methyl-coumarin.
Fluorescence was measured (absorption at 360 nm and
emission at 460 nm) using an FLX 800 microplate fluor-
escence reader (Bio-Tek Instruments, Winooski, VT).
Cell culture and maintenance
The RAW 264.7 cells or mouse peritoneal macrophages
were maintained in DMEM supplemented with 10%
heat inactivated fetal bovine serum (FBS) and 10 mg
gentamicin (in 500 mL) at 37°C in a humidified atmo-
sphere with 5% CO2 as described previously [27]. Cells
were cultured in 6-well plates as described in the
legends to the figures.
Effects of δ-tocotrienol (concentrations of 10 - 640 μM)
after 60 min treatment on different proteasomal activities
(chymotrypsin-like, trypsin-like, and postglutamase) in
RAW 264.7 whole cells
In order to check the comparative inhibitory effect of
tocols, only the most potent δ-tocotrienol was tested on
the chymotrypsin-like, trypsin-like, and post-glutamase
activities of the proteasome using RAW 264.7 whole
cells; the following experiment was carried out. RAW
264.7 cells (10 × 10
4 cells/100 μl/well) were added in
white plates 96-well, Fisher, 0877126), followed by the
addition of various concentrations of δ-tocotrienol (10,
20, 40, 80, 160, 320, or 640 μM in 100 μL; dissolved in
0.2% dimethyl sulfoxide (DMSO). The mixtures were
incubated at 37°C in an incubator at 5% CO2 for 60 min.
After incubation period, the cells in the 96-well plates
were taken out 20 min prior to the addition of Caspase-
Glo reagent (brought to room temperature before addi-
tion to the wells). Caspase-Glo reagent (100 μL) was
added to each well to a total volume of 200 μL/well (tris
b u f f e r ,p H7 . 5 ;0 . 0 2M ) .T h ep l a t ew e r ec o v e r e dw i t ha
plate sealer, removed from light and incubated at room
temp for 10 min. The relative luminescence units (RLU)
of assays were read with a Promega Plate Luminometer.
The chymotrypsin-like, trypsin-like, or post-glutamase
activities were quantitated by measuring luminescence
after stimulation of RAW 264.7 whole cells with various
doses of δ-tocotrienol in a Luminometer (Promega),
according to the directions of manufacturer.
Effects of various tocols (a-tocopherol, a-tocotrienol,
g-tocotrienol or δ-tocotrienol) on the secretion of TNF-a
in LPS-stimulated RAW 264.7 cells
The levels of TNF-a in RAW 264.7 cell culture superna-
tants were determined after treatment with LPS (1 ng/
mL) and various doses (4, 8, 16 μM) of a-tocopherol,
a-tocotrienol, g-tocotrienol or δ-tocotrienol by Quanti-
kine M ELISA kit (R&D System, Minneapolis, MN)
according to manufacturer’s instructions. The lower
limit of detection for TNF-a in this method is approxi-
mately, 5.0 pg/mL [28,29]. The TNF-a levels in mouse’s
serum or thioglycollate-elicited peritoneal macrophages
were also quantified by using the same method [28,29].
Effects of a-, g-, and δ-tocotrienols on release of LPS-
induced TNF-a in serum of 6-wk-old female BALB/c mice
All mice used in this study received humane care in
compliance with the principles of laboratory animal
care formulated by the National Society of Health
Guide for the Care and Use of Laboratory Animals
(DHHS Publication No. [NIH] 85 - 23, revised 1985).
The experimental procedures involving animals were
reviewed and approved by the Institutional Animal
Care and Use Committee of UMKC, Medical School,
M O .F e m a l eB A L B / cm i c ew e r ea c c l i m a t i z e dt ot h e
new environment for fourteen days and were fedad
libitum regular commercial mice diet and had free
access to water throughout the experiment. A 12 h
light and 12 h dark cycle was maintained during feed-
ing period. All samples were dissolved in 5% triethyla-
mine solution.
S e v e ng r o u p so f4 - w k - o l df e m a l eB A L B / cm i c e( 3 /
group) were acclimatized (for two wks), and then injected
either with saline (two control groups), dexamethazone or
various doses (2.5, 5.0, and 10.0 μg/kg body weight) of a-
tocopherol, a-tocotrienol, g-tocotrienol, or δ-tocotrienol.
One h later, all mice were injected intraperitoneally with
pure LPS (E. coli D31m4; 10 ng/mouse). After two h, all
mice were sacrificed, serum was collected, and the levels
of TNF-a were quantified using a radioimmunoassay kit
according to the manufacturer’s directions [28,29].
Effects of a-, g-, and δ-tocotrienols on the induction of
corticosterone and adrenocorticotropic hormone (ACTH)
in serum of LPS-stimulated 6-wk-old female BALB/c mice
To further probe the anti-inflammatory effects of various
tocotrienols in mice, we queried whether tocotrienols
would also induce the serum levels of corticosterone and
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ment of mice as reported recently [3]. The levels of
serum (used from the above experiment) corticosterone
and ACTH were estimated according to published
method [1,3].
Isolation of thioglycollate-elicited peritoneal macrophages
from BALB/c mice, total cellular RNA isolation and RT-PCR
Ten 4-wk-old female BALB/c mice were acclimatized to
the new environment for fourteen days, and thioglycol-
late-elicited peritoneal macrophages were prepared as
described previously [29]. Macrophages (2 × 10
5)w e r e
treated with either pure LPS (10 ng/treatment), LPS +
a-tocopherol (25, 50, or 100 μM), LPS + δ-tocotrienol
(10, 20, or 40 μM). All the samples were dissolved in
0.2% dimethyl sulfoxide (DMSO). The assay mixtures
were incubated at room temperature for 4 h and then
centrifuged at 2,000 rpm for 20 min. The supernatants
were removed and concentrations of TNF-a were deter-
mined using Quantikine M ELISA kit (R&D System,
Minneapolis, MN) according to the manufacturer’s
directions [29]. The total RNA was isolated from each
pellet with RNeasy mini kit according to the manufac-
turer’s instructions. To check the purity of the total
RNA, Reverse transcriptase polymerase chain reaction
(RT-PCR) was conducted using a 1-step kit (Qiagen,
Chatsworth, CA) according to the manufacturer’s
instructions.
Detection of cell viability
Viability of peritoneal macrophages treated with and
without LPS plus dexamethasone (positive control),
a-tocopherol or various doses of δ-tocotrienol was
determined by trypan blue dye exclusion or a quantita-
tive colorimetric assay with 3-(4,5)-dimethylthiozol-2,5-
diphenyltetrazolium bromide (MTT) as described pre-
viously [30].
Statistical analyses
The analyses demonstrated the affect of various isomers
of tocols (a-tocopherol or a-, g-, δ-tocotrienols) within
the groups. Stat View software (version 4.01, Abacus
Concepts, Berkeley, CA) was used for the analyses of
treatment-mediated effects as compared to the control
group. Treatment-mediated differences in various
inflammatory markers variables were evaluated using a
two-way ANOVA, and when F test indicated a signifi-
cant effect, the differences between the means were ana-
lyzed by a Fisher’s protected least significant and least
difference test. Data were reported as means ± SD in
text and Tables. The level for statistical significance
level was established at 5% (P < 0.05).
Results
The results of the present study on the inhibition of
inflammation by tocotrienols are presented in the same
in two different formats. For each figure, ‘A’ shows the
raw values for each of the treatments and controls, and
‘B’ shows the percent change compared to controls.
Inhibition of chymotrypsin-like activity of 20 S rabbit
muscle proteasomes by various tocols (tocopherols +
tocotrienols)
We have previously shown that the proteasome is a cen-
tral regulator of inflammation; we therefore queried
whether tocotrienols also affect proteasome activity, thus
affecting the induction of cytokines. The results of this
study reveals that inhibition of chymotrypsin-like activity
of the 20 S rabbit muscle proteasomes was dose-
dependent between 4 μMa n d1 6μMf o ra-tocotrienol
(6% - 36%), g-tocotrienol (12% - 32%), and δ-tocotrienol
(51% - 55%) as compared to control groups (Figure 2A
&2B). An insignificant reduction (5%) in 20 S pro-
teasomes activity was observed with a-tocopherol
(Figure 2A &2B). These studies further suggest that
δ-tocotrienol is the most effective isomer of the tocotrie-
nols for inhibiting the chymotrypsin-like activity of rabbit
muscle proteasomes.
Impact of δ-tocotrienol (concentrations of 10 - 640 μM)
on different proteasomal active sites (chymotrypsin-like,
trypsin-like, and post-glutamase) in RAW 264.7 whole
cells after 60 min treatment
The effects of δ-tocotrienol on the chymotrypsin-like,
trypsin-like, and post-glutamase activities of protea-
somes were also carried out in RAW 264.7 murine
macrophages. The chymotrypsin-like activities decreased
to 46% of controls with 40 μM δ-tocotrienol treatment
of cells and then increased gradually as shown in
Figure 3. A similar trend was observed with the trypsin-
like activity and post-glutamase activities in response to
δ-tocotrienol (Figure 3).
Inhibition of the secretion of TNF-a in LPS-stimulated
RAW 264.7 cells by various tocols (a-tocopherol,
a-tocotrienol, g-tocotrienol or δ-tocotrienol)
The effects of tocotrienols on the secretion of TNF-a
with, and without, LPS-stimulation in RAW 264.7 cells
was investigated. A significant reduction of secretion of
TNF-a, 9% - 33% (P < 0.05) was observed with tocotrie-
nols in LPS-stimulated RAW 264.7 cells in a dose-
dependent manner (Figure 4A &4B). Tocotrienols did
not inhibit TNF-a secretion in the absence of LPS sti-
mulation (data not shown in the figure). Cell viability
for all above experiments was 90% - 95%.
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Figure 2 Effects of various tocol treatments on the chymotrypsin-like activity of 20 S rabbit muscle proteasomes.C h y m o t r y p s i n - l i k e
activity was carried out by using synthetic dipeptide substrate III (Suc-Leu-Leu-Val-Tyr-AMC) in buffer pH 7.5, 0.02 M. Rabbit muscle proteasomes
were used. The compounds were dissolved in 2% dimethyl sulfoxide (DMSO). Fluorescence absorption was measured at excitation = 360 nm
and emission = 460 nm, A = values; B = percentages.
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Page 5 of 15a-, g-, and δ-Tocotrienols reduced serum TNF-a levels in
LPS-stimulated 6-wk-old BALB/c mice
To further probe the anti-inflammatory effects of var-
ious tocols in mice, we queried whether dietary supple-
mentation with tocotrienols would also block LPS-
induced TNF-a secretion in mice. A dose-dependent
inhibition (20% to 48%; P <0 . 0 5 )o fL P S - i n d u c e ds e r u m
TNF-a levels was observed with a-, g-, and δ-tocotrie-
nols as compared to control diets (Figure 5A &5B). The
reduction with a-tocopherol (5% - 9%) was insignificant
as compared to control or tocotrienol treatments (Figure
5A &5B). These results also suggest that δ-tocotrienol is
the most effective isomer in reducing LPS-induced
TNF-a secretion in mice.
a-, g-, and δ-Tocotrienols induce corticosterone in serum
of 6-wk-old BALB/c mice
We have previously shown that LPS treatment of mice
induces high endogenous corticosterone levels, and that
corticosterone levels are inversely correlated with TNF-
a serum concentrations [9]. Therefore, to further
explore mechanisms responsible for the anti-inflamma-
tory effects of tocotrienols, we queried whether tocols
increase corticosterone levels produced in response to
LPS. For this experiment BALB/c mice were injected i.p.
with tocotrienols. A significant (P < 0.02) rise in LPS-
induced serum corticosterone (19%, 31%, and 41%)
levels was induced by treatment with a-, g-, or δ-toco-
trienols as compared to the control group (Figure 6A
&6B). These results suggest that the decrease in the
synthesis of TNF-a c o u l db ed u et ot h er i s ei n
the endogenous corticosteroids, which may modulate
the synthesis of inflammatory cytokines [3].
a-, g-, and δ-Tocotrienols induce adrenocorticotropic
hormone in serum of 6-wk-old BALB/c mice
The impact of a-tocopherol and various tocotrienols on
the levels of adrenocorticotropic hormone was also
determined in the serum obtained from the experiment
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Figure 3 Effects of δ-tocotrienol (concentration 10 μM - 640 μM) on proteasomal active sites, chymotrypsin-like, trypsin-like and post-
glutamase, after 60 min treatment of RAW 264.7 whole cells. Proteasome-Glo (Promega) chymotrypsin-like, trypsin-like, and post-glutamase
cell based assays were carried out. 10,000 cells were plated per well in 100 μL of media in a 96-well white colored plate. Cells were allowed to
adhere to plates for 2 h prior to testing. At the start of the test, media or 0.4% DMSO + media (used as control = CD), or δ-tocotrienol
(concentrations 10 μM - 640 μM) dissolved in 0.4% DMSO were added to each well for a duration of 1 h. The mixtures in the plates were
assayed according to Promega Protocol. Plates were read with a “Promega Luminometer” according to the directions of manufacturer, which
give relative luminescence units (RLV) values.
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Figure 4 Effects of various tocols on secretion of TNF-a in LPS-stimulated RAW 264. 7 cells. RAW 264.7 cells (500 μL) were adhered in wells
for 2 h at room temperature. The cells were then treated with various concentrations of a-tocopherol, or a-, g-, or δ-tocotrienols (100 μL) for 1 h, then
the wells were treated with LPS (1 ng/well; 400 μL) for 4 h. The supernatants were then transferred in glass vials and stored at -20°C for subsequent
TNF-a assays. Cell viability was determined for all treatment and control groups. The experimental solution were prepared by dissolving highest
concentration amount of a-tocopherol or a-, g-, δ-tocotrienols in 1.0 mL DMSO = X. Solution × (50 μL) was mixed with 950 μL of media = Y. The
remaining required concentrations were prepared with Y (1:2 dilutions). The TNF-a assays were carried out using an ELISA kit, and kit control value
varies 266 - 444 (287), A = values; B = percentages.
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Figure 5 Effect of various tocols on serum TNF-a levels in LPS-stimulated, 6-week-old female BALB/c mice. The BALB/c female mice
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Page 8 of 15described above. A corresponding significant (P < 0.02)
dose-dependent rise in LPS-induced serum adrenocortico-
tropic hormone levels was observed (81%, 118%, and
145%) by treatment with a-, g-, or δ-tocotrienols, respec-
tively, as compared with the control group (Figure 7A
&7B). An insignificant rise in the levels of corticosterone
(7%) and adrenocorticotropic hormone (14%) with a-toco-
pherol was also observed (Figure 6B &7B). In summary,
these results clearly indicate that δ-tocotrienol is most
effective in inhibiting the serum levels of TNF-a and also
in inducing the serum levels of corticosterone and adreno-
corticotropic hormone as compared to a-, g-tocotrienols
and a-tocopherol, which were the least effective com-
pounds as compared to their respective control groups.
δ-Tocotrienol inhibits LPS-induced TNF-a, IL-1b, IL-6, and
iNOS gene expression in thioglycollate-elicited peritoneal
macrophages of 6-wk-old BALB/c mice
In order to define the mechanism of action of tocotrienols
with respect to lowering inflammation, thioglycollate-eli-
cited peritoneal macrophages were prepared from BALB/c
female mice, and treated with a-tocopherol, or δ-tocotrie-
nol 1 h before, or at the same time as LPS. After 4 h of the
treatment, total cellular RNA was extracted and reverse-
transcribed, and gene analysis was performed by RT-PCR
and southern blot analyses. The results of gene expression
studies clearly demonstrate that δ-tocotrienol is most
effective in blocking LPS-induced gene expression of
TNF-a Figure 8A &8B, IL-1b, IL-6 and iNOS at low doses
of 10 μMa n d2 0μM (Figure 9A &9B).
There were significant (P < 0.02) reductions of TNF-a
(45%), IL-1b (63%), IL-6 (46%) and iNOS (32%) mRNA
w i t had o s eo f2 0μM compared to their respective con-
trol values, and significant increases (40%, 17%, 26%,
13%) in the levels of these mRNA’s, with a dose of 40 μM
of δ-tocotrienol, as compared to their respective 20 μM
control values (Figure 8B &9B). These results are in
agreement with earlier results of tocotrienols on the
activities of chymotrypsin-like, trypsin-like and post-
glutamase in RAW 264.7 whole cells (Figure 3). The
a-tocopherol (doses of 25, 50 or 100 μM) did not have
any impact on the gene expression of TNF-a, IL-1b,I L - 6
and iNOS compared to their respective control values
(Figure 8A, Figure 9B).
Discussion
It is well established that LPS-induced TNF-a produc-
tion requires activation of NF-B and activation of pro-
teasomal activity. The results presented here
demonstrate that tocotrienols block production of key
pro-inflammatory cytokines induced by LPS. We
hypothesized that this blockade of LPS-induced inflam-
mation by tocotrienols could be due to modulation of
proteasomal activity [31], since tocotrienols have been
shown to be effective inhibitors of b-hydroxy-b-methylglu-
taryl coenzyme A (HMG-CoA) reductase, (the rate-limit-
ing enzyme in cholesterol biosynthesis), and are very
potent antioxidant and hypocholesterolemic agents [12]. It
has also been demonstrated that HMG-CoA reductase is
degraded via the ubiquitin-proteasome pathway [32,33].
We have shown that tocotrienols can inhibit chymotryp-
sin-like activity of 20 S rabbit muscle proteasome, and that
δ-tocotrienol specifically inhibits the chymotrypsin-like,
trypsin-like and post-glutamase activities of the protea-
some in a dose-dependent manner in RAW 264.7 whole
cells at concentrations below 80 μM; at higher concentra-
tions (80 - 640 μM) tocotrienole enhance these activities
as has been previously reported for lactacystin [34,35].
Tocotrienols also inhibit the LPS-stimulated secretion
of TNF-a in RAW 264.7 cells and in serum of BALB/c
mice, and a corresponding significant (P <0 . 0 2 )r i s ew a s
observed in the serum levels of corticosterone and adre-
nocorticotropic hormone compared to controls. More-
over, δ-Tocotrienol is effective in reducing LPS-induced
gene expression of TNF-a,I L - 1 b IL-6 and iNOS at low
concentrations. Interestingly, at high concentrations
δ-Tocotrienol activates chymotrypsin-like, trypsin-like,
and post-glutamase activities, and upregulates LPS-
induced gene expression of TNF-a,I L - 1 b,I L - 6a n d
iNOS. It seems that tocotrienols actually upregulates the
proteasomal activity, and thus can upregulate LPS-
stimulated transcription of several pro-inflammatory
genes at higher concentrations. Therefore, the capacity of
δ-tocotrienol to modulate inflammation may be attribu-
table, in part, to inhibition and activation of the chymo-
trypsin-like, trypsin-like and post-glutamase’ activities of
mouse macrophages.
The present results also demonstrated that δ-tocotrie-
nol is the most effective tocol among the known, a-a n d
g-tocotrienols for inhibition or induction of various cyto-
kines involved in inflammation, whereas a-tocopherol
does not play any role in inhibiting LPS-induced inflam-
mation. This conclusion has been further confirmed in a
recent study [32] which demonstrated that δ-tocotrienol
is very effective in inducing ubiquitination and degrada-
tion of HMG-CoA reductase. δ-tocotrienol also blocks
the processing of sterol regulatory element-binding pro-
teins-2 (SREBPs-2) which, when activated, can enhance
transcription of genes encoding cholesterol biosynthetic
enzymes, including HMG-CoA reductase [32]. On the
other hand, tocopherols neither increase degradation of
reductase, nor decrease SREBP-2 processing [32].
The unsaturated isoprenoid side-chain in tocotrienol
molecules is important for its biological activity and it
was suggested that this could stimulate binding of
HMG-CoA reductase to Insig (endoplasmic reticulum
membrane protein). Alternatively, the side-chain might
allow improved penetration and distribution in cell
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Page 9 of 15membranes [32,33]. This may contribute to the differ-
ences observed in the potency of tocotrienols versus
tocopherols in stimulating HMG-CoA reductase in vitro
ubiquitination [32,33] thus confirming our previous and
present results showing that δ-tocotrienol (one methyl
group) is more potent than g-tocotrienol (two methyl
groups) due to the number of methyl groups which
abolishes regulatory activity with respect to HMG-CoA
reductase degradation and SREBP-2 processing
[10,11,32].
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Figure 6 Effects of a-tocopherol, a-tocotrienol, g-tocotrienol and δ-tocotrienol on the induction of corticosterone in serum of LPS-
stimulated 6-wk-old BALB/c female mice. Three mice for each concentration were injected i.p. with tocols in 5% triethylamine solution (0.2
mL/mouse) one h prior to LPS challenge, after conditioning them for 14 days. Mice were bled after 2 h later to collect serum. Serum
corticosterone levels were determined according to a published procedure (3). Values in a column with a different superscript letters are
significantly different at P < 0.05, A = values; B = percentages.
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Figure 7 Effects of a-tocopherol, a-tocotrienol, g-tocotrienol and δ-tocotrienol on the induction of adrenocorticotropic hormone in
serum of LPS-stimulated 6-wk-old BALB/c female mice. Three mice for each concentration were injected i. p. with various tocols in 5%
triethylamine solution (0.2 mL/mouse) one hr prior to LPS challenge, after conditioning them for 14 days. Mice were bled after 2 h later to
collect serum. Serum adrenocorticotropic hormone levels were determined according to published procedure (3). Values in a column with a
different superscript letters are significantly different at P < 0.05, A = values; B = percentages.
Qureshi et al. Lipids in Health and Disease 2010, 9:143
http://www.lipidworld.com/content/9/1/143
Page 11 of 150
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8 0.76
0.56
0.42
0.72
0.76 0.74
0.78 0.78
R
T
-
P
C
R
 
 
(
R
a
t
i
o
s
 
o
f
 
O
p
t
i
c
a
l
 
D
e
n
s
i
t
y
 
o
f
 
T
N
F
-
D
/
E
-
A
c
t
i
n
)
.
A
TNF-alpha TNF-alpha
0
20
40
60
80
100
120
100
74
55
95
100 97
103 103
P
e
r
c
e
n
t
a
g
e
s
 
o
f
 
R
T
-
P
C
R
 
 
(
R
a
t
i
o
s
 
o
f
O
p
t
i
c
a
l
 
D
e
n
s
i
t
y
 
o
f
 
T
N
F
-
D
/
E
-
A
c
t
i
n
)
. B
TNF-Alpha
Figure 8 Effects of a-tocopherol and δ-tocotrienol on the gene expression of TNF-a in LPS-stimulated peritoneal macrophages of
6-week-old BALB/c female mice. The RT-PCR procedure is described in the experimental section. The ratios of relative optical density (TNF-a/
b-actin) of each treatment for TNF-a was used to draw this figure, A = values; B = percentages.
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Figure 9 Effects of a-tocopherol and δ-tocotrienol on the gene expression of IL-1b, IL-6, and iNOS in LPS-stimulated peritoneal
macrophages of 6-week-old BALB/c female mice. The RT-PCR procedure is described in the experimental section. The ratios of relative
optical density (cytokines/b-actin) of each treatment for each marker was used to draw this figure, A = values; B = percentages.
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Although LPS is a potent inducer of inflammation via
the proteasome, it also activates an anti-inflammatory
response by inducing corticosteroid production. In sum-
mary, δ-tocotrienol treatment has several anti-inflamma-
tory effects that could be mechanistically analogous to
the modulation of proteasomal activity by lactacystin, a
well established proteasome inhibitor that can either
increase or decrease proteasomal activity under different
conditions [34,35]. The results of our current study also
demonstrate that tocotrienols increase levels of adreno-
corticotropic hormone (ACTH) and corticosteroids pro-
duced in response to LPS. The mechanisms by which
LPS plus tocotrienols stimulate the hypothalamus-
pituitary-adrenal (HPA) axis and the sites of action are
currently unclear [3]. Regardless of the mechanism,
however, the capacity of tocotrienols to increase the
host corticosteroid response to LPS is likely to modulate
inflammation. Other possible mechanisms for the anti-
inflammatory properties of tocotrienols also include its
superior antioxidant activity compared to a-tocopherol
(vitamin E, [10,17,22]). All these latter mechanisms such
as corticosteroid induction and antioxidant activities
may be dependent on the proteasomal modulation by
tocotrienols.
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